<DOC>
	<DOCNO>NCT00359541</DOCNO>
	<brief_summary>This study look voriconazole , drug use treat protect fungal infection , affect body . Adverse effect associate voriconazole include skin problem temporary change vision , mental status liver function . There evidence side effect may intense high level drug blood . The amount voriconazole body determine much drug patient receive patient 's ability inactivate excrete , may determine part gene . This study examine : 1 ) side effect patient develop voriconazole ; 2 ) whether side effect experience related concentration drug body ; 3 ) role gene determine quickly body inactivate excrete drug . Patients 12 old participate study National Institute Allergy Infectious Diseases ( NIAID ) , National Cancer Institute ( NCI ) National Heart , Lung , Blood Institute ( NHLBI ) treat voriconazole 15 day less may eligible study . Participation involve follow : - Identification record adverse effect patient experience due voriconazole treatment - Collection basic information patient 's medical history treatment - Blood draws week patient 's hospitalization - Collection routine laboratory test result order patient 's doctor - Blood draw identify gene responsible voriconazole inactivation - Weekly monitoring possibility voriconazole adverse effect - Blood draw measure blood level voriconazole drug stop , stop adverse effect - Evaluations outpatient visit , include blood draw measure voriconazole blood level Participation study end 7 day voriconazole treatment stop long need .</brief_summary>
	<brief_title>Voriconazole Blood Levels Toxicity</brief_title>
	<detailed_description>Voriconazole ( Vfend ( Registered Trademark ) , Pfizer ) achieve common usage NIH ( National Institutes Health ) Clinical Research Center treatment fungal infection immunosuppressed patient . Toxicity include relatively frequent reversible change vision infrequent , potentially serious hepatotoxicity , decrease cognitive function rash . Incidence serious adverse event difficult ascertain morbidity underlying disease patient receive voriconazole , minimum estimate 10 percent . It known voriconazole plasma concentration vary patient fifty-fold range know whether toxicity relate plasma drug exposure . The reason differ voriconazole plasma concentration normal individual partly due genetic variation hepatic cytochrome enzyme CYP2C9 CYP2C19 ( Cytochrome P450 , family 2 , subfamily C , polypeptide 9 19 , respectively ) . In patient underlie illness , drug interaction decrease hepatic drug clearance may contribute variability . The purpose study record prospectively adverse effect voriconazole Clinical Center patient prescribed drug primary physician . We ask primary physician order trough voriconazole plasma level week . The test report physician . Because interpretation test unknown , physician blind report . Rather , primary objective study analyze voriconazole plasma concentration study complete determine concentration duration drug exposure correlate toxicity . A secondary objective determine 2C9 2C19 genotype patient search possible correlation genotype plasma voriconazole concentration . Administration drug give patient track analyze whether previously unknown drug interaction seem change voriconazole plasma concentration . The study also determine incidence adverse effect voriconazole patient population .</detailed_description>
	<mesh_term>Voriconazole</mesh_term>
	<criteria>INCLUSION CRITERIA : Patients , least 12 year old restriction gender , race disability , follow National Institute Allergy Infectious Diseases ( NIAID ) , National Cancer Institute ( NCI ) National Heart Lung Blood Institute ( NHLBI ) begin treatment voriconazole either oral intravenous . Patients previous voriconazole course least 7 day current course . EXCLUSION CRITERIA : Time elapse great 15 day initiation voriconazole treatment inpatient great 30 day initiation voriconazole treatment outpatient . Patients medical staff care patient want enter study . Patients unable give inform consent , due severity medical condition ( Comatose patient , ICU patient sedation ) .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 25, 2010</verification_date>
	<keyword>CYP2C9</keyword>
	<keyword>CYP2C19</keyword>
	<keyword>Pharmacology</keyword>
	<keyword>Genotype</keyword>
	<keyword>Metabolism</keyword>
</DOC>